tiprankstipranks
Agios Pharmaceuticals (CH:8AP)
NASDAQ:8AP
Switzerland Market
8AP
Agios Pharma
RESEARCH TOOLSreports

Agios Pharma (8AP) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

8AP Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
3 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Agios
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

8AP Stock 12 Month Forecast

Average Price Target

$31.78
Based on 8 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is $31.78 with a high forecast of $43.63 and a low forecast of $25.05. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$43.63Average Price Target$31.78Lowest Price Target$25.05
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:8AP
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
CHF43.63
Buy
―
Reiterated
07/13/26
H.C. Wainwright Remains a Buy on Agios Pharma (AGIO)
Leerink Partners Analyst forecast on CH:8AP
Andrew Berens
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)
Truist Financial Analyst forecast on CH:8AP
Gregory Renza
Truist Financial
Truist Financial
CHF29.08→CHF33.12
Buy
―
Reiterated
07/07/26
Agios Pharmaceuticals price target raised to $41 from $36 at TruistAgios Pharmaceuticals price target raised to $41 from $36 at Truist
Bank of America Securities Analyst forecast on CH:8AP
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF32.32→CHF37.16
Buy
―
Reiterated
07/07/26
Bank of America Securities Keeps Their Buy Rating on Agios Pharma (AGIO)
RBC Capital Analyst forecast on CH:8AP
Luca Issi
RBC Capital
RBC Capital
CHF22.62→CHF25.85
Hold
―
Reiterated
07/07/26
Agios Pharmaceuticals price target raised to $32 from $28 at RBC CapitalAgios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
TD Cowen Analyst forecast on CH:8AP
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on CH:8AP
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF25.85
Hold
―
Reiterated
06/14/26
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
J.P. Morgan Analyst forecast on CH:8AP
Tessa Romero
J.P. Morgan
J.P. Morgan
CHF29.08→CHF25.05
Hold
―
Assigned
06/11/26
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)
Citi Analyst forecast on CH:8AP
Samantha Semenkow
Citi
Citi
CHF37.16
Buy
―
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Omeros (NASDAQ: OMER) and Agios Pharma (NASDAQ: AGIO)
Scotiabank Analyst forecast on CH:8AP
Greg Harrison
Scotiabank
Scotiabank
CHF52.51
Buy
―
Reiterated
08/05/25
Scotiabank Remains a Buy on Agios Pharma (AGIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:8AP
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
CHF43.63
Buy
―
Reiterated
07/13/26
H.C. Wainwright Remains a Buy on Agios Pharma (AGIO)
Leerink Partners Analyst forecast on CH:8AP
Andrew Berens
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)
Truist Financial Analyst forecast on CH:8AP
Gregory Renza
Truist Financial
Truist Financial
CHF29.08→CHF33.12
Buy
―
Reiterated
07/07/26
Agios Pharmaceuticals price target raised to $41 from $36 at TruistAgios Pharmaceuticals price target raised to $41 from $36 at Truist
Bank of America Securities Analyst forecast on CH:8AP
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF32.32→CHF37.16
Buy
―
Reiterated
07/07/26
Bank of America Securities Keeps Their Buy Rating on Agios Pharma (AGIO)
RBC Capital Analyst forecast on CH:8AP
Luca Issi
RBC Capital
RBC Capital
CHF22.62→CHF25.85
Hold
―
Reiterated
07/07/26
Agios Pharmaceuticals price target raised to $32 from $28 at RBC CapitalAgios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
TD Cowen Analyst forecast on CH:8AP
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on CH:8AP
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF25.85
Hold
―
Reiterated
06/14/26
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
J.P. Morgan Analyst forecast on CH:8AP
Tessa Romero
J.P. Morgan
J.P. Morgan
CHF29.08→CHF25.05
Hold
―
Assigned
06/11/26
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)
Citi Analyst forecast on CH:8AP
Samantha Semenkow
Citi
Citi
CHF37.16
Buy
―
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Omeros (NASDAQ: OMER) and Agios Pharma (NASDAQ: AGIO)
Scotiabank Analyst forecast on CH:8AP
Greg Harrison
Scotiabank
Scotiabank
CHF52.51
Buy
―
Reiterated
08/05/25
Scotiabank Remains a Buy on Agios Pharma (AGIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
LGNDLigand Pharma
KURAKura Oncology
EHCEncompass Health
VKTXViking Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

3 Months
Emily BodnarH.C. Wainwright
Success Rate
11/16 ratings generated profit
69%
Average Return
+8.26%
Copying Emily Bodnar's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +8.26% per trade.
1 Year
Emily BodnarH.C. Wainwright
Success Rate
11/16 ratings generated profit
69%
Average Return
+20.56%
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +20.56% per trade.
2 Years
Andrew BerensLeerink Partners
Success Rate
14/16 ratings generated profit
88%
Average Return
+54.42%
Copying Andrew Berens's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +54.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8AP Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
4
6
7
7
4
Buy
8
9
11
15
14
Hold
3
6
6
9
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
21
24
31
23
In the current month, 8AP has received 18 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 8AP average Analyst price target in the past 3 months is 31.78.
Each month's total comprises the sum of three months' worth of ratings.

8AP Financial Forecast

8AP Earnings Forecast

Next quarter’s earnings estimate for 8AP is -$1.35 with a range of -$1.64 to -$1.20. The previous quarter’s EPS was -$1.38. 8AP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.
Next quarter’s earnings estimate for 8AP is -$1.35 with a range of -$1.64 to -$1.20. The previous quarter’s EPS was -$1.38. 8AP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.

8AP Sales Forecast

Next quarter’s sales forecast for 8AP is $21.22M with a range of $17.59M to $24.59M. The previous quarter’s sales results were $16.89M. 8AP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.
Next quarter’s sales forecast for 8AP is $21.22M with a range of $17.59M to $24.59M. The previous quarter’s sales results were $16.89M. 8AP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 8AP has Performed in-line its overall industry.

8AP Stock Forecast FAQ

What is CH:8AP’s average 12-month price target, according to analysts?
Based on analyst ratings, Agios Pharmaceuticals’s 12-month average price target is 31.78.
    What is CH:8AP’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:8AP, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Agios Pharmaceuticals a Buy, Sell or Hold?
        Agios Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Agios Pharmaceuticals’s share price target?
          The average share price target for Agios Pharmaceuticals is 31.78. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $43.63 ,and the lowest forecast is $25.05. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Agios Pharmaceuticals?
            Agios Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
              How can I buy shares of Agios Pharmaceuticals?
              To buy shares of CH:8AP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.